Internship

2025 Co-op

Delivery Science-Analytical Research

Posted on 9/11/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Cambridge, MA, USA

Co-op opportunity in Cambridge, MA from January 21, 2025 – June 20, 2025.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • Current Junior or Senior student enrolled in a bachelor program in Chemistry, Chemical Engineering, Biochemical Engineering, Biomedical Engineering, or a related field
  • Experience working in a lab; knowledge of general chemical safety protocols
  • Fundamental knowledge of analytical techniques and lab procedures.
Responsibilities
  • Perform experiments using various analytical techniques, such as chromatography, spectroscopy, and mass spectrometry
  • Support the development and validation of analytical methods
  • Support the formulation of LNPs
  • Analyze and interpret experimental data, and communicate research findings across departments
  • Maintain good documentation practice and detailed scientific records of experiments
  • Collaborate with cross-functional teams on the research projects
  • Maintain and troubleshoot laboratory instruments

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treatment options for patients. Unlike traditional pharmaceuticals, which often rely on small molecules or proteins, Moderna's mRNA-based therapies aim to enhance the discovery, development, and manufacturing processes of medicines. The company's goal is to leverage the unique properties of mRNA to improve patient outcomes and create a new category of effective treatments.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

16%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's AI-driven drug discovery accelerates novel mRNA-based therapeutics identification.
  • Expansion in Asia enhances global supply chain and reduces production costs.
  • mRNA technology is gaining traction for non-infectious disease vaccines, like cancer.

What critics are saying

  • Potential Nasdaq 100 removal could impact stock visibility and investor interest.
  • Bypassing safety steps in Australia may raise regulatory and public scrutiny concerns.
  • Hong Kong's reluctance to receive Covid-19 jab affects market penetration and sales.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company focuses on mRNA's potential to transform drug discovery and manufacturing.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE